| OS | CSS | LRFFS | DFFS | |||||
---|---|---|---|---|---|---|---|---|---|
HR (95 % CI) | P | HR (95 % CI) | P | HR (95 % CI) | P | HR (95 % CI) | P | ||
Univeriate parameter | |||||||||
 Age | Continuous variable | 1.051(0.977–1.131) | 0.185 | 1.046 (0.967–1.132) | 0.261 | 0.892(0.737–1.079) | 0.239 | 1.044(0.945–1.154) | 0.399 |
 Gender | male vs. female | 1.301(0.590–2.869) | 0.514 | 1.119(0.504–2.487) | 0.782 | 2.131(0.277–16.397) | 0.467 | 1.434(0.433–4.751) | 0.555 |
 T-stage | T1-2 vs. T3-4 | 0.907(0.496–1.659) | 0.752 | 0.974(0.518–1.833) | 0.936 | 2.725(0.915–8.115) | 0.072 | 0.984(0.418–2.320) | 0.971 |
 N-stage | N0-1vs. N2-3 | 0.902(0.538–1.512) | 0.902 | 1.087(0.628–1.883) | 0.765 | 1.200(0.403–3.570) | 0.744 | 0.763(0.361–1.614) | 0.479 |
 Clinical stage | I-II vs. III-IV | 0.805(0.291–2.228) | 0.805 | 0.929(0.334–2.580) | 0.887 | 2.088(0.462–9.430) | 0.338 | 0.436(0.059–3.209) | 0.415 |
 NP dose (Gy) | Continuous variable | 1.007(0.930–1.090) | 0.862 | 1.002(0.921–1.090) | 0.960 | 0.925(0.808–1.058) | 0.253 | 1.042(0.923–1.175) | 0.510 |
 LN dose (Gy) | Continuous variable | 1.023(0.980–1.068) | 0.292 | 1.021(0.975–1.068) | 0.380 | 0.946(0.871–1.027) | 0.187 | 1.057(0.993–1.125) | 0.083 |
 RT Days | Continuous variable | 1.006(0.981–1.032) | 0.623 | 1.010(0.984–1.037) | 0.451 | 0.954(0.887–1.026) | 0.203 | 1.013(0.977–1.050) | 0.493 |
 Treatment group | IC + RT vs. CCRT | 0.717(0.421–1.220) | 0.220 | 0.682(0.388–1.198) | 0.183 | 0.747(0.244–2.284) | 0.609 | 1.709(0.693–4.218) | 0.245 |
 Cranial nerve involvement | absent vs. present | 0.781(0.354–1.726) | 0.542 | 0.663(0.298–1.476) | 0.314 | 0.581(0.128–2.628) | 0.481 | 0.657(0.228–1.896) | 0.437 |
 Basicranial Bone involvement | absent vs. present | 0.553(0.329–0.929) | 0.025 | 0.558(0.321–0.969) | 0.038 | 0.784(0.263–2.341) | 0.663 | 0.712(0.339–1.497) | 0.371 |
 Family history | absent vs. present | 1.142(0.413–3.155) | 0.798 | 1.349(0.420–4.335) | 0.615 | 22.74(0.003–25.96) | 0.494 | 0.655(0.197–2.171) | 0.489 |
Multivariate parametera | |||||||||
 Treatment group | IC + RT vs. CCRT | 0.706(0.412–1.208) | 0.204 | 0.708(0.402–1.246) | 0.231 | 0.696(0.207–2.342) | 0.558 | 1.627(0.658–4.023) | 0.292 |
 Basicranial Bone involvement | absent vs. present | 0.553(0.329–0.929) | 0.025 | 0.558(0.321–0.969) | 0.038 | 0.246(0.044–1.382) | 0.111 | 0.760(0.337–1.715) | 0.508 |
 T-stage | T1-2 vs. T3-4 | 1.347(0.638–2.842) | 0.435 | 1.490(0.675–3.289) | 0.324 | 6.833(1.224–38.148) | 0.028 | 1.355(0.481–3.819) | 0.565 |